Domitor 1 mg/ml inj. sol. i.m./i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

domitor 1 mg/ml inj. sol. i.m./i.v. vial

orion corp. - medetomidine hydrochloride 1 mg/ml - solution for injection - 1 mg/ml - medetomidine hydrochloride 1 mg/ml - medetomidine - dog; cat

Dorbene Vet 1 mg/ml inj. sol. s.c./i.v./i.m. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

dorbene vet 1 mg/ml inj. sol. s.c./i.v./i.m. vial

laboratorios syva s.a.u. - medetomidine hydrochloride 1 mg/ml - eq. medetomidine 0,85 mg/ml - solution for injection - 1 mg/ml - medetomidine hydrochloride 1 mg/ml - medetomidine - dog; cat

Medetor 1 mg / ml inj. sol. i.m./i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

medetor 1 mg / ml inj. sol. i.m./i.v. vial

cp-pharma handelsgesellschaft gmbh - medetomidine hydrochloride 1 mg/ml - eq. medetomidine 0,85 mg/ml - solution for injection - 1 mg / ml - medetomidine hydrochloride 1 mg/ml - medetomidine - dog; cat

Narcostart 1 mg/ml inj. sol. i.m./i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

narcostart 1 mg/ml inj. sol. i.m./i.v. vial

le vet pharma b.v. - medetomidine hydrochloride 1 mg/ml - eq. medetomidine 0,85 mg/ml - solution for injection - 1 mg/ml - medetomidine hydrochloride 1 mg/ml - medetomidine - dog; cat

Sedator 1 mg /ml inj. sol. i.m./i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sedator 1 mg /ml inj. sol. i.m./i.v. vial

dechra regulatory - medetomidine hydrochloride 1 mg/ml - eq. medetomidine 0.85 mg/ml - solution for injection - 1 mg /ml - medetomidine hydrochloride 1 mg/ml - medetomidine - dog; cat

Sededorm 1 mg/ml inj. sol. i.m./i.v./s.c. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sededorm 1 mg/ml inj. sol. i.m./i.v./s.c. vial

vetpharma animal health s.l. - medetomidine hydrochloride 1 mg/ml - eq. medetomidine 0,85 mg/ml - solution for injection - 1 mg/ml - medetomidine hydrochloride 1 mg/ml - medetomidine - dog; cat

DEXMEDETOMIDINE HYDROCHLORIDE- dexmedetomidine hydrochloride injection, solution United States - English - NLM (National Library of Medicine)

dexmedetomidine hydrochloride- dexmedetomidine hydrochloride injection, solution

actavis pharma, inc. - dexmedetomidine hydrochloride (unii: 1018wh7f9i) (dexmedetomidine - unii:67vb76hono) - dexmedetomidine 100 ug in 1 ml - dexmedetomidine hydrochloride injection is indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures. none teratogenic effects: pregnancy category c there are no adequate and well-controlled studies of dexmedetomidine hydrochloride injection use in pregnant women. in an in vitro human placenta study, placental transfer of dexmedetomidine occurred. in a study in the pregnant rat, placental transfer of dexmedetomidine was observed when radiolabeled dexmedetomidine was administered subcutaneously. thus, fetal exposure should be expected in humans, and dexmedetomidine hydrochloride injection should be used during pregnancy only if the potential benefits justify the potential risk to the fetus. teratogenic effects were not observed in rats following subcutaneous administration of dexmedetomidine during the period of fetal organogenesis (from gestation day 5 to 16) with doses up to 200 mcg/kg (representing a dose approximately equal to the maximum recommended human intra

DEXMEDETOMIDINE HYDROCHLORIDE injection, solution United States - English - NLM (National Library of Medicine)

dexmedetomidine hydrochloride injection, solution

sun pharmaceuticals industries, inc. - dexmedetomidine hydrochloride (unii: 1018wh7f9i) (dexmedetomidine - unii:67vb76hono) - dexmedetomidine 100 ug in 1 ml - dexmedetomidine hydrochloride injection is indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures. none pregnancy category c: there are no adequate and well-controlled studies of dexmedetomidine hydrochloride use in pregnant women.  in an in vitro human placenta study, placental transfer of dexmedetomidine occurred. in a study in the pregnant rat, placental transfer of dexmedetomidine was observed when radiolabeled dexmedetomidine was administered subcutaneously.  thus, fetal exposure should be expected in humans, and dexmedetomidine hydrochloride should be used during pregnancy only if the potential benefits justify the potential risk to the fetus. teratogenic effects were not observed in rats following subcutaneous administration of dexmedetomidine during the period of fetal organogenesis (from gestation day 5 to 16) with doses up to 200 mcg/kg (representing a dose approximately equal to the maximum recommended human intravenous dose based on body surface

DEXMEDETOMIDINE injection, solution DEXMEDETOMIDINE HYDROCHLORIDE- dexmedetomidine hydrochloride in 0.9% sodium chloride inject United States - English - NLM (National Library of Medicine)

dexmedetomidine injection, solution dexmedetomidine hydrochloride- dexmedetomidine hydrochloride in 0.9% sodium chloride inject

eugia us llc - dexmedetomidine hydrochloride (unii: 1018wh7f9i) (dexmedetomidine - unii:67vb76hono) - dexmedetomidine 100 ug in 1 ml - dexmedetomidine injection is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. dexmedetomidine injection should be administered by continuous infusion not to exceed 24 hours. dexmedetomidine injection has been continuously infused in mechanically ventilated adult patients prior to extubation, during extubation, and post-extubation. it is not necessary to discontinue dexmedetomidine injection prior to extubation. dexmedetomidine injection is indicated for sedation of non-intubated adult patients prior to and/or during surgical and other procedures. pediatric use information is approved for hospira inc.’s precedextm (dexmedetomidine hydrochloride) injection and precedextm (dexmedetomidine hydrochloride) in sodium chloride injection. however, due to hospira inc.’s marketing exclusivity rights, this drug product is not labeled with that information. none. risk summary available data from published randomized controll

DEXMEDETOMIDINE HYDROCHLORIDE injection, solution United States - English - NLM (National Library of Medicine)

dexmedetomidine hydrochloride injection, solution

fresenius kabi usa, llc - dexmedetomidine hydrochloride (unii: 1018wh7f9i) (dexmedetomidine - unii:67vb76hono) - dexmedetomidine 100 ug in 1 ml - dexmedetomidine hydrochloride injection is indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures. none. pregnancy category c there are no adequate and well-controlled studies of dexmedetomidine hydrochloride injection use in pregnant women.  in an in vitro human placenta study, placental transfer of dexmedetomidine occurred.  in a study in the pregnant rat, placental transfer of dexmedetomidine was observed when radiolabeled dexmedetomidine was administered subcutaneously.  thus, fetal exposure should be expected in humans, and dexmedetomidine hydrochloride injection should be used during pregnancy only if the potential benefits justify the potential risk to the fetus. teratogenic effects were not observed in rats following subcutaneous administration of dexmedetomidine during the period of fetal organogenesis (from gestation day 5 to 16) with doses up to 200 mcg/kg (representing a dose approximately equal to the maximum recommended human intravenous dose base